TYRATyra Biosciences, Inc.

$26.23

$10.1052 weeks$39.61

Price

$26.23+144%1Y

1M-15%1Y+144%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Average

6/10

Value43

Quality52

Momentum74

Growth-

Strongest Momentum, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. Our in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help us design and predict which product candidates may demonstrate the highest potency, selectivity and tolerability in the clinic.

In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$1.68B

1Y Return+144%

5Y Return-